FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN

oncodaily - On May 27, 2026, the U.S. FDA granted approval to pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid […]

AI Summary: The FDA approved pivekimab sunirine (Decnupaz/pvzy), the first antibody‑drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking a regulatory win for an ultra‑rare blood cancer. The decision underscores ADCs’ growing role in niche hematologic malignancies and anchors AbbVie’s expanding ADC strategy.

#pharmaceuticals #biotech #drugdevelopment #fda #oncology #cancerresearch #clinicaltrials

Paolo Tarantino: Packed Educational Session on Novel ADCs

15 hrs / oncodaily

Kelly Shanahan: Interesting ASCO 2026 Discussion on ADC Ocular Side Effects

37 hrs / oncodaily

KEYNOTE-905 at ASCO 2026: HRQoL With Perioperative EV/Pembrolizumab in Cisplatin-Ineligible MIBC

38 hrs / oncodaily

FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN

3 days / oncodaily

FDA Approved Pivekimab Sunirine‑Pvzy for Adult Patients – BPDCN International Registry

3 days / oncodaily

AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer

3 days / medcitynews / Frank Vinluan

Tag Directory / FDA showing 1–1 of 1 RSS

for: Saturday, May 30, 2026

FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN

FDA Heatmap